[20190312]LSB10272_2019年《创建法案》和降低药品价格:法律背景和概述.pdf

上传人:任我行 文档编号:28009 上传时间:2022-06-24 发布时间:2019-04-12 格式:PDF 页数:5 大小:585.70KB
下载 相关 举报
[20190312]LSB10272_2019年《创建法案》和降低药品价格:法律背景和概述.pdf_第1页
第1页 / 共5页
[20190312]LSB10272_2019年《创建法案》和降低药品价格:法律背景和概述.pdf_第2页
第2页 / 共5页
[20190312]LSB10272_2019年《创建法案》和降低药品价格:法律背景和概述.pdf_第3页
第3页 / 共5页
[20190312]LSB10272_2019年《创建法案》和降低药品价格:法律背景和概述.pdf_第4页
第4页 / 共5页
[20190312]LSB10272_2019年《创建法案》和降低药品价格:法律背景和概述.pdf_第5页
第5页 / 共5页
亲,该文档总共5页,全部预览完了,如果喜欢就下载吧!
资源描述

1、CRS Legal Sidebar Prepared for Members and Committees of Congress Legal SidebarLegal Sidebari i The CREATES Act of 2019 and Lowering Drug Prices: Legal Background & Overview March 12, 2019 On February 5, 2019, the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 (CREATES Act) wa

2、s reintroduced in both the Senate and the House. The bill, first introduced in the 114th Congress (S. 3056) and again in the 115th Congress (S. 974 and H.R. 2212), aims to facilitate the timely entry of lower-cost generic and biosimilar versions of brand-name drugs and biological products (i.e., pro

3、ducts such as vaccines and blood components that are derived from living organisms) to promote competition in the market for such products. Specifically, the CREATES Act aims to address the concern that some brand manufacturers have improperly restricted the distribution of their products, including

4、 by invoking a distribution safety protocol known as Risk Evaluation and Mitigation Strategies (REMS), to deny generic product developers access to samples of brand products. (For ease of reference, this Sidebar uses “generic product” to refer to both generic drugs and biosimilars). Because generic

展开阅读全文
相关资源
猜你喜欢
相关搜索
资源标签

当前位置:首页 > 法规条令 > CRS 美国国会研究处报告